Table 3.
Frequency of antimicrobial non-susceptibility in three major epidemic lineages in the 69 CNSAb isolates.
| % Non-susceptibility to CLSI antimicrobial groupsa |
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICb (No.) | A |
B |
O |
|||||||||||||||
| IPM | MEM | CAZ | SAM | AMK | TOB | GEN | CIP | PIP | TZP | FEP | MIN | TET | TGC | LVX | SXT | CST | RIF | |
| IC1 (13) | 100 | 100 | 100 | 85 | 92 | 62 | 92 | 100 | 100 | 100 | 100 | 48 | 46 | 9 | 100 | 100 | 0 | 100 |
| IC2 (25) | 100 | 92 | 88 | 48 | 84 | 76 | 88 | 88 | 96 | 92 | 96 | 19 | 32 | 5 | 88 | 96 | 0 | 92 |
| V (31) | 100 | 100 | 100 | 61 | 84 | 61 | 100 | 97 | 100 | 97 | 100 | 25 | 39 | 24 | 97 | 100 | 0 | 97 |
| Total (69) | 100 | 97 | 96 | 65 | 86 | 66 | 93 | 95 | 99 | 96 | 97 | 31 | 39 | 13 | 95 | 99 | 0 | 97 |
aConsiderations in the assignment of agents to Groups A, B, and C include clinical efficacy, prevalence of resistance, minimizing emergence of resistance, cost, FDA clinical indications for usage, and current consensus recommendations for first-choice and alternative drugs. Group A are considered appropriate for inclusion in a routine, primary testing panel, as well as for routine reporting of results for the specific organism. Group B comprises agents that may warrant primary testing. Group O (Other) includes agents that have a clinical indication for the organism. Escherichia coli ATCC25922 and Pseudomonas aeruginosa ATCC27853 were used for quality control of antimicrobial susceptibility testing and included in each run.
bIC, international clonal lineage; V, IC variants; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colisitin; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; PIP, piperacillin; RIF, rifampicin; SAM, ampicillin-sulbactam; SXT, trimethoprim- sulfamethoxazole; TET, tetracycline; TGC, tigecycline; TOB, tobramicin; TZP, piperacillin-tazobactam.